Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 1,263 | 179 | 1,073 |
| Samples | 1,146 | 161 | 974 |
| Peptides | 749 | 114 | 670 |
Function
CARD11 · Caspase recruitment domain family member 11
The protein encoded by this gene belongs to the membrane-associated guanylate kinase (MAGUK) family, a class of proteins that functions as molecular scaffolds for the assembly of multiprotein complexes at specialized regions of the plasma membrane. This protein is also a member of the CARD protein family, which is defined by carrying a characteristic caspase-associated recruitment domain (CARD). This protein has a domain structure similar to that of CARD14 protein. The CARD domains of both proteins have been shown to specifically interact with BCL10, a protein known to function as a positive regulator of cell apoptosis and NF-kappaB activation. When expressed in cells, this protein activated NF-kappaB and induced the phosphorylation of BCL10. [provided by RefSeq, Jul 2008].
Isoforms & Proteins
1 transcript · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
| Transcript | UniProt | Mutations | Peptides |
|---|---|---|---|
| ENST00000396946 | Q9BXL7 | 1,263 | 749 |
Gene Properties
Recurrent Mutations
All 749 amino-acid changes on canonical ENST00000396946 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in CARD11 · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in CARD11 – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| T-Lymphoblastic Leukemia | 9/40 22% | 0/0 0% |
| Melanoma | 19/210 9% | 152/1899 8% |
| Chronic Myelogenous Leukemia | 2/25 8% | 0/0 0% |
| Endometrial Carcinoma | 12/42 29% | 37/612 6% |
| Chordoma | 0/7 0% | 1/13 8% |
| Non-Small Cell Lung Carcinoma | 25/304 8% | 59/1390 4% |
| Other Solid Cancers | 3/94 3% | 73/1515 5% |
| Colorectal Carcinoma | 15/143 10% | 141/3239 4% |
| Glioblastoma | 4/98 4% | 0/0 0% |
| B-Cell Non-Hodgkins Lymphoma | 12/88 14% | 94/2534 4% |
| Gastric Carcinoma | 2/74 3% | 54/1809 3% |
| Osteosarcoma | 1/45 2% | 5/166 3% |
| Squamous Cell Lung Carcinoma | 7/57 12% | 15/810 2% |
| Cervical Carcinoma | 0/35 0% | 11/422 3% |
| Gastrointestinal Stromal Tumour | 0/0 0% | 3/133 2% |
| Burkitts Lymphoma | 2/32 6% | 3/196 2% |
| Bladder Carcinoma | 1/58 2% | 21/956 2% |
| Hodgkins Lymphoma | 2/16 12% | 1/122 1% |
| Neuroendocrine Tumour | 9/154 6% | 4/577 1% |
| Hepatocellular Carcinoma | 1/46 2% | 39/2210 2% |
| Adrenocortical Carcinoma | 0/3 0% | 2/112 2% |
| Small Cell Lung Carcinoma | 0/9 0% | 13/752 2% |
| Germ Cell Tumour | 1/25 4% | 2/169 1% |
| Esophageal Carcinoma | 2/23 9% | 10/769 1% |
| Other Blood Cancers | 3/61 5% | 35/2725 1% |
| Mesothelioma | 2/62 3% | 1/165 1% |
| Non-Cancerous | 2/104 2% | 10/830 1% |
| Esophageal Squamous Cell Carcinoma | 2/51 4% | 31/2550 1% |
| Ovarian Carcinoma | 5/109 5% | 9/998 1% |
| Breast Carcinoma | 10/144 7% | 33/3264 1% |
Mutation Distribution
Where CARD11 is mutated · all tissues, split by cell line vs tissue
How many mutations in CARD11 were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
GTEx Expression
Median TPM across 54 healthy tissues
Median gene expression (TPM) in normal, non-cancer human tissues from the GTEx project.
Useful for judging tumour specificity – a strong neoantigen target ideally comes from a gene with low expression in healthy tissues.
Scroll or drag the mini-axis below the chart to browse all tissues.
Mutations
All 1,263 mutations in CARD11
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|